The following drug companies made headlines this past week.
1. Mylan keeps EpiPen costs high despite intense public scrutiny
Despite immense public scrutiny, a CMS rebate scandal and several federal hearings all spurred by the product's price, a two-pack of Mylan's EpiPens maintains its $609 list price.
2. Lung Therapeutics completes $14.3M Series B financing to develop treatments for lung disease
Lung Therapeutics on Tuesday said it raised $14.3 million in a Series B financing.
3. Allergan to acquire Keller Medical
Allergan Sales — a subsidiary of drugmaker Allergan — will acquire the privately-owned devicemaker Keller Medical for an undisclosed amount.
4. Advocacy group calls for FDA action on Bayer's birth control device
A patient advocacy group is calling on the Food and Drug Administration to take action against Bayer Healthcare's Essure sterilization coils as women continue to be harmed by the product.
5. AstraZeneca divests migraine drug for $302M
AstraZeneca on Wednesday sold its migraine treatment Zomig to German drugmaker Grunenthal in a deal worth $302 million.
6. Pfizer makes 2nd price hike this year for nearly 100 drugs
Pfizer on June 1 increased the U.S. list prices for nearly 100 drugs in its second price hike of the year.
7. Eli Lilly CFO to retire at year-end
Eli Lilly CFO Derica Rice is retiring in December 2017, ending a 27-year career with the global pharmaceutical giant.
More articles on supply chain:
4 ways hospitals can lower inpatient drug costs
6 must-reads for supply chain leaders this week
AMA physicians: Pharma should be required to divulge drug prices in consumer-facing ads